Hepatitis B surface antigen variants in voluntary blood donors in Nanjing, China

Virology Journal

Volumn 9, Issue , 2012, Pages

  Yang, Yong Lin ^a,b   Fu, Qiang ^a   Zhang, Ming Shun ^b,c   Cai, Jie ^b   Ma, Gui Ming ^a   Huang, Zu Hu ^b   Cai, Xu Bing ^a  

^a Nanjing Red Cross Blood Center   (China)

^b THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^c NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Genotype; Hepatitis B surface antigen; Hepatitis B virus; Mutation

Indexed keywords

HEPATITIS B SURFACE ANTIGEN;

ADULT; ARTICLE; BLOOD DONOR; CHINA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE AMPLIFICATION; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC VARIABILITY; GENOTYPE; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; MALE; RED CROSS; SEROTYPE; VIRUS STRAIN; VOLUNTARY BLOOD DONOR;

HEPATITIS B VIRUS;

EID: 84859707372     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-9-82     Document Type: Article

References (41)

1. Hepatitis B in China. Liu J, Fan D, Lancet 2007 369 9573 1582 1583 10.1016/S0140-6736(07)60723-5 17499584 (Pubitemid 46710107)
2. Control of hepatitis B in China: prevention and treatment. Wang Y, Jia J, Expert Rev Anti Infect Ther 2011 9 1 21 25 10.1586/eri.10.143 21171874
3. Prevalence of hepatitis B in the southeast of China: a population-based study with a large sample size. Luo Z, Xie Y, Deng M, Zhou X, Ruan B, Eur J Gastroenterol Hepatol 2011 23 8 695 700 10.1097/MEG.0b013e328347322b 21617533
4. Seroprevalence and risk factors for hepatitis B infection in an adult population in Northeast China. Zhang H, Li Q, Sun J, Wang C, Gu Q, Feng X, Du B, Wang W, Shi X, Zhang S, Li W, Jiang Y, Feng J, He S, Niu J, Int J Med Sci 2011 8 4 321 331 PMCID: 3100740 21611114
5. Hepatitis B virus transfusion risk in China: proficiency testing for the detection of hepatitis B surface antigen. Zhang R, Wang L, Li J, Transfus Med 2010 20 5 322 328 10.1111/j.1365-3148.2010.01007.x 20409073
6. Two HBV DNA+/HBsAg- blood donors identified by HBV NAT in Shenzhen, China. Shang G, Yan Y, Yang B, Shao C, Wang F, Li Q, Seed CR, Transfus Apher Sci 2009 41 1 3 7 10.1016/j.transci.2009.05.001 19487161
7. Residual risk of transfusion-transmitted viral infections in Shenzhen, China, 2001 through 2004. Shang G, Seed CR, Wang F, Nie D, Farrugia A, Transfusion 2007 47 3 529 539 10.1111/j.1537-2995.2006.01146.x 17319836
8. A study on aetiological factors of primary hepato-carcinoma in Tianjin China. Lin J, Zhonghua Liu Xing Bing Xue Za Zhi 1991 12 6 346 349 1667380
9. One example of false negative hepatitis B surface antigen (EIA) result due to variant S area strain and reagment reactiveness related to hepatitis B surface antigen. Matsuda C, Moriyama H, Taketani T, Shibata H, Nagai A, Kansenshogaku Zasshi 2011 85 1 21 25 21404602
10. Biological significance of amino acid substitutions in hepatitis B surface antigen (HBsAg) for glycosylation, secretion, antigenicity and immunogenicity of HBsAg and hepatitis B virus replication. Wu C, Zhang X, Tian Y, Song J, Yang D, Roggendorf M, Lu M, Chen X, J Gen Virol 2010 91 Pt 2 483 492 19812261
11. A novel nucleotide insertion in S gene of hepatitis B virus in a chronic carrier. Tong W, Sun L, He J, He S, Du F, Virol J 2010 7 104 PMCID: 2893152 10.1186/1743-422X-7-104 20492719
12. Monitoring of hepatitis B virus surface antigen escape mutations and concomitantly nucleos(t)ide analog resistance mutations in Turkish patients with chronic hepatitis B. Sayan M, Senturk O, Akhan SC, Hulagu S, Cekmen MB, Int J Infect Dis 2010 14 Suppl 3 136 e141 20382061
13. Prediction of conformational changes by single mutation in the hepatitis B virus surface antigen (HBsAg) identified in HBsAg-negative blood donors. Ie SI, Thedja MD, Roni M, Muljono DH, Virol J 2010 7 326 PMCID: 2998485 10.1186/1743-422X-7-326 21087462
14. Transmission of "a" determinant variants of hepatitis B virus in immunized babies born to HBsAg carrier mothers. Velu V, Saravanan S, Nandakumar S, Dhevahi E, Shankar EM, Murugavel KG, Kumarasamy T, Thyagarajan SP, Jpn J Infect Dis 2008 61 1 73 76 18219140 (Pubitemid 351338536)
15. Molecular characterization of a variant virus that caused de novo hepatitis B without elevation of hepatitis B surface antigen after chemotherapy with rituximab. Miyagawa M, Minami M, Fujii K, Sendo R, Mori K, Shimizu D, Nakajima T, Yasui K, Itoh Y, Taniwaki M, Okanoue T, Yoshikawa T, J Med Virol 2008 80 12 2069 2078 10.1002/jmv.21311 19040281
16. Antigenic properties of mutant hepatitis B virus surface antigen. Guo MZ, Yi Y, Chen SY, Bai Y, Jia ZY, Bi SL, Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 2008 22 1 48 50 18414700
17. Frequency and significance of hepatitis B virus surface gene variant circulating among 'antiHBc only' individuals in Eastern India. Banerjee A, Chandra PK, Datta S, Biswas A, Bhattacharya P, Chakraborty S, Chakrabarti S, Bhattacharya SK, Chakravarty R, J Clin Virol 2007 40 4 312 317 10.1016/j.jcv.2007.08.009 17997353 (Pubitemid 350151995)
18. Transmission of G145R mutant of HBV to an unrelated contact. Thakur V, Kazim SN, Guptan RC, Hasnain SE, Bartholomeusz A, Malhotra V, Sarin SK, J Med Virol 2005 76 1 40 46 10.1002/jmv.20321 15778957 (Pubitemid 40446453)
19. Survey of hepatitis B surface variant infection in children 15 years after a nationwide vaccination programme in Taiwan. Hsu HY, Chang MH, Ni YH, Chen HL, Gut 2004 53 10 1499 1503 PMCID: 1774240 10.1136/gut.2003.034223 15361503 (Pubitemid 39265274)
20. Wild-type and 'a' epitope variants in chronic hepatitis B virus carriers positive for hepatitis B surface antigen and antibody. Mesenas SJ, Chow WC, Zhao Y, Lim GK, Oon CJ, Ng HS, J Gastroenterol Hepatol 2002 17 2 148 152 10.1046/j.1440-1746.2002.02627.x 11966944 (Pubitemid 34415667)
21. Prevalence of mutants in the determinant region of hepatitis B surface antigen among Chinese carriers after receiving only active postexposure immunoprophylaxis. Xia G, Nainan OV, Jia Z, Wang JJ, Liu HB, Li RC, Cao HL, Liu CB, Margolis HS, Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 2001 15 3 212 215 11986686
22. A new HBsAg screening assay designed for sensitive detection of HBsAg subtypes and variants. van Roosmalen MH, de Jong JJ, Haenen W, Jacobs T, Couwenberg F, Ahlers-de Boer GJ, Hellings JA, Intervirology 2006 49 3 127 132 10.1159/000089373 16428888 (Pubitemid 43131544)
23. Blood donation screening for hepatitis B virus markers in the era of nucleic acid testing: are all tests of value? Stramer SL, Zou S, Notari EP, Foster GA, Krysztof DE, Musavi F, Dodd RY, Transfusion 2011 52 2 440 446 21810101
24. Assessment of nucleic acid testing (NAT) for screening hepatitis B in blood donors. Systematic review. Ruiz-Aragon J, Marquez-Pelaez S, Invest Clin 2010 51 3 341 349 21305771
25. Can the nucleic acid amplification test (NAT) be an alternative to the serologic tests? A prospective study, the results of 18,200 blood donors from the Turkish Red Crescent. Kosan E, Kocazeybek B, Altunay H, Aymelek M, Alan E, Saribas S, Aslan M, Yenen OS, Yuksel P, Birinci I, Kirali K, Aksoy A, Transfus Apher Sci 2010 43 3 269 272 10.1016/j.transci.2010.09.013 20943441
26. The cost-effectiveness of introducing nucleic acid testing to test for hepatitis B, hepatitis C, and human immunodeficiency virus among blood donors in Sweden. Davidson T, Ekermo B, Gaines H, Lesko B, Akerlind B, Transfusion 2011 51 2 421 429 10.1111/j.1537-2995.2010.02877.x 20849409
27. Quality and Safety in Blood Supply in 2010. Seitz R, Heiden M, Transfus Med Hemother 2010 37 3 112 117 PMCID: 2889628 10.1159/000314497 20577599
28. Efficacy of individual nucleic acid amplification testing in reducing the risk of transfusion-transmitted hepatitis B virus infection in Switzerland, a low-endemic region. Stolz M, Tinguely C, Graziani M, Fontana S, Gowland P, Buser A, Michel M, Canellini G, Zuger M, Schumacher P, Lelie N, Niederhauser C, Transfusion 2010 50 12 2695 2706 10.1111/j.1537-2995.2010.02732.x 20573074
29. A cost-benefit analysis of blood donor vaccination as an alternative to additional DNA testing for reducing transfusion transmission of hepatitis B virus. Fischinger JM, Stephan B, Wasserscheid K, Eichler H, Gartner BC, Vaccine 2010 28 49 7797 7802 10.1016/j.vaccine.2010.09.037 20875488
30. Hepatitis B virus genotypes and evolutionary profiles from blood donors from the northwest region of China. Hu XB, Yue QH, Zhang XQ, Xu XQ, Wen Y, Chen YZ, Cheng XD, Yang L, Mu SJ, Virol J 2009 6 199 PMCID: 2781008 10.1186/1743-422X-6-199 19917138
31. Analysis of HBs antigen negative variant of hepatitis B virus: unique substitutions, Glu129 to Asp and Gly145 to Ala in the surface antigen gene. Koyanagi T, Nakamuta M, Sakai H, Sugimoto R, Enjoji M, Koto K, Iwamoto H, Kumazawa T, Mukaide M, Nawata H, Med Sci Monit 2000 6 6 1165 1169 11208474 (Pubitemid 32009578)
32. The analysis of "a" dominant mutation of hepatitis B virus in community-based population of Shandong Province, China. Zhang L, Yan BY, Ji F, Li MS, Song LZ, Xu AQ, Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 2010 24 6 424 426 21604565
33. Molecular characteristics of occult hepatitis B virus from blood donors in southeast China. Yuan Q, Ou SH, Chen CR, Ge SX, Pei B, Chen QR, Yan Q, Lin YC, Ni HY, Huang CH, Yeo AE, Shih JW, Zhang J, Xia NS, J Clin Microbiol 2010 48 2 357 362 PMCID: 2815617 10.1128/JCM.01781-09 19940057
34. Detection of hepatitis B virus DNA among accepted blood donors in Nanjing, China. Liu Y, Li P, Li C, Zhou J, Wu C, Zhou YH, Virol J 2010 7 193 PMCID: 2931482 10.1186/1743-422X-7-193 20718994
35. Occult hepatitis B virus infection: detection and significance. Gerlich WH, Bremer C, Saniewski M, Schuttler CG, Wend UC, Willems WR, Glebe D, Dig Dis 2010 28 1 116 125 10.1159/000282074 20460899
36. Genotyping the hepatitis B virus with a fragment of the HBV DNA polymerase gene in Shenyang, China. Ma Y, Ding Y, Juan F, Dou XG, Virol J 2011 8 315 PMCID: 3132165 10.1186/1743-422X-8-315 21693069
37. Characterization of occult hepatitis B virus infection from blood donors in China. Zheng X, Ye X, Zhang L, Wang W, Shuai L, Wang A, Zeng J, Candotti D, Allain JP, Li C, J Clin Microbiol 2011 49 5 1730 1737 PMCID: 3122685 10.1128/JCM.00145-11 21411575
38. Occult HBV infection in anti-HBs-positive young adults after neonatal HB vaccination. Xu L, Wei Y, Chen T, Lu J, Zhu CL, Ni Z, Huang F, Du J, Sun Z, Qu C, Vaccine 2010 28 37 5986 5992 10.1016/j.vaccine.2010.06.106 20637763
39. Genetic variability in hepatitis B viruses. Kidd-Ljunggren K, Miyakawa Y, Kidd AH, J Gen Virol 2002 83 Pt 6 1267 1280 12029141 (Pubitemid 34591320)
40. Hepatitis B surface antigen variants in vaccinees, blood donors and an interferon-treated patient. Seddigh-Tonekaboni S, Lim WL, Young B, Hou JL, Waters J, Luo KX, Thomas HC, Karayiannis P, J Viral Hepat 2001 8 2 154 158 10.1046/j.1365-2893.2001.00275.x 11264736 (Pubitemid 32234869)
41. Diagnostic impact of the genetic variability of the hepatitis B virus surface antigen gene. Weber B, J Med Virol 2006 78 Suppl 1 59 S65 16622880